Literature DB >> 9146612

The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population.

C H Bangma1, J B Rietbergen, R Kranse, B G Blijenberg, K Petterson, F H Schröder.   

Abstract

PURPOSE: The ratio between free and total prostate specific antigen (PSA) in serum improves the specificity of total serum PSA for the detection of prostate carcinoma in select populations. The value of the free-to-total PSA ratio for a PSA of 4.0 to 10.0 ng./ml. was analyzed in a screening population.
MATERIALS AND METHODS: From 4,800 participants 55 to 76 years old 977 biopsies were obtained because of an abnormal digital rectal examination, suspicious transrectal ultrasonography and total serum PSA 4.0 ng./ml. or more. Of 191 patients with prostate carcinoma detected 101 had a serum PSA of 4.0 to 10.0 ng./ml. and 54 of them underwent radical prostatectomy. A free-to-total PSA ratio of 0.20, age specific PSA reference ranges and a PSA density of 0.12 ng./ml./cc were evaluated for the ability to increase the specificity of total serum PSA in predicting positive prostate biopsy results.
RESULTS: Receiver operating characteristics curves for the free-to-total PSA ratio showed a significant increase in specificity compared to PSA. Retrospective application of age specific PSA reference ranges, the free-to-total PSA ratio and the PSA density decreased the number of biopsies significantly by up to 40% in our study, with a decrease in cancer detection rate of 12%. When used in combination with digital rectal examination, the pathological stage of undetected carcinomas appeared favorable.
CONCLUSIONS: The free-to-total PSA ratio may be used to decrease biopsies in patients with an intermediate PSA of 4.0 to 10.0 ng./ml.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9146612

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  9 in total

Review 1.  Screening for prostate cancer.

Authors:  S R Gambert
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

2.  Diagnostic efficacy of free to total ratio of prostate-specific antigen and prostate-specific antigen velocity, singly and in combination, in detecting prostate cancer in patients with total serum prostate-specific antigen between 4 and 10 ng/ml.

Authors:  Shingo Yamamoto; Takuo Maruyama; Nobuyuki Kondoh; Michio Nojima; Hidekazu Takiuchi; Seiichi Hirota; Hiroki Shima
Journal:  Int Urol Nephrol       Date:  2007-07-06       Impact factor: 2.370

3.  Impact of assay parameters on the accuracy of free PSA test: source and stability of calibrator, calibration curve fitting, and level of total PSA in the serum.

Authors:  G H Liu; J T Wu
Journal:  J Clin Lab Anal       Date:  1998       Impact factor: 2.352

4.  Improved discrimination of prostate cancer and benign prostatic hyperplasia by means of the quotient of free and total PSA.

Authors:  D Weckermann; C Maassen; F Wawroschek; R Harzmann
Journal:  Int Urol Nephrol       Date:  1999       Impact factor: 2.370

5.  Using the free-to-total prostate-specific antigen ratio to detect prostate cancer in men with nonspecific elevations of prostate-specific antigen levels.

Authors:  R M Hoffman; D L Clanon; B Littenberg; J J Frank; J C Peirce
Journal:  J Gen Intern Med       Date:  2000-10       Impact factor: 5.128

6.  Detection of telomerase activity in prostate massage samples improves differentiating prostate cancer from benign prostatic hyperplasia.

Authors:  Carlo Vicentini; Giovanni Luca Gravina; Adriano Angelucci; Esterina Pascale; Ettore D'Ambrosio; Paola Muzi; Gabriella Di Leonardo; Antonio Fileni; Andrea Tubaro; Claudio Festuccia; Mauro Bologna
Journal:  J Cancer Res Clin Oncol       Date:  2004-01-29       Impact factor: 4.553

7.  Probability of prostate cancer as a function of the percentage of free prostate-specific antigen in patients with a non-suspicious rectal examination and total prostate-specific antigen of 4-10 ng/ml.

Authors:  L Martínez-Piñeiro; J M García Mediero; P González Gancedo; A Tabernero; D Lozano; J J López-Tello; J M Alonso-Dorrego; C Núñez; M L Picazo; R Madero; J J De La Peña
Journal:  World J Urol       Date:  2004-02-20       Impact factor: 4.226

Review 8.  Overdiagnosis and overtreatment of early detected prostate cancer.

Authors:  C H Bangma; S Roemeling; F H Schröder
Journal:  World J Urol       Date:  2007-02-14       Impact factor: 4.226

9.  Development and clinical testing of individual immunoassays for the quantification of serum glycoproteins to diagnose prostate cancer.

Authors:  Kathrin Endt; Jens Goepfert; Aurelius Omlin; Alcibiade Athanasiou; Pierre Tennstedt; Anna Guenther; Maurizio Rainisio; Daniel S Engeler; Thomas Steuber; Silke Gillessen; Thomas Joos; Ralph Schiess
Journal:  PLoS One       Date:  2017-08-02       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.